Schering suffers delay on Zevalin EU launch
This article was originally published in Clinica
German company Schering is to delay the launch of its radioimmunotherapy product Zevalin (90Y-ibritumomab tiuxetan) in the EU because of certain technical compliance issues. The Berlin-based company, which had planned to launch the product in the second half of 2002, says it is examining all options to release the product as quickly as possible - hopefully in the second half of 2003. Zevalin is the first radioimmunotherapy treatment for certain Non-Hodgkins Lymphoma. Schering stressed that the clinical efficacy of the product was not in question.